BioCryst Pharmaceuticals CEO Jon Stonehouse's 2019 pay falls 45% to $2.3M
BioCryst Pharmaceuticals reports 2019 executive compensation
By ExecPay News
Published: March 31, 2020
BioCryst Pharmaceuticals reported fiscal year 2019 executive compensation information on March 31, 2020.
In 2019, five executives at BioCryst Pharmaceuticals received on average a compensation package of $1.5M, a 35% decrease compared to previous year.
Average pay of disclosed executives at BioCryst Pharmaceuticals
Jon P. Stonehouse, Chief Executive Officer, received $2.3M in total, which decreased by 45% compared to 2018. 60% of Stonehouse's compensation, or $1.4M, was in option awards. Stonehouse also received $351K in non-equity incentive plan, $550K in salary, as well as $15K in other compensation.
Megan T. Sniecinski, Senior Vice President and Chief Business Officer, received a compensation package of $2.2M. 81% of the compensation package, or $1.8M, was in option awards.
Yarlagadda S. Babu, Senior Vice President of Drug Discovery, earned $1.1M in 2019, a 38% decrease compared to previous year.
William P. Sheridan, Chief Medical Officer, received $1.1M in 2019, which decreases by 55% compared to 2018.
Thomas R. Staab II, Chief Financial Officer, earned $910K in 2019, a 49% decrease compared to previous year.
Related executives
Jon Stonehouse
BioCryst Pharmaceuticals
Chief Executive Officer
Thomas Staab
BioCryst Pharmaceuticals
Chief Financial Officer
Yarlagadda Babu
BioCryst Pharmaceuticals
Chief Discovery Officer
William Sheridan
BioCryst Pharmaceuticals
Chief Medical Officer
Megan Sniecinski
BioCryst Pharmaceuticals
Former Chief Business Officer
You may also like
Source: SEC filing on March 31, 2020.